Otsuka Pharmaceutical Gets Exclusive Rights For Three Plasma Substitutes From Fresenius Kabi
This article was originally published in PharmAsia News
Executive Summary
Otsuka Pharmaceutical Factory Inc. signed an exclusive agreement May 21 for the sale of three hydroxyethyl starch, or HES preparations used as plasma substitutes with Fresenius Kabi Japan.